Enlivex Announces Pricing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Key Highlights
- ➤Enlivex prices $7.5 million registered direct offering at $1.315 per share and warrant
- ➤Ordinary warrants carry $1.578 exercise price, expire three years, and could add $9.0 million
- ➤Investors commit $700,000 monthly across ten subsequent closings through September 2027
- ➤Enlivex may pay qualifying investors 5% of certain future commercial or asset-sale proceeds
Nes-Ziona, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with certain investors for the purchase and sale, in a registered direct offering, of an aggregate of $7,500,000 of the Company’s ordinary shares (or pre-funded warrants in lieu thereof), together with accompanying ordinary warrants to purchase up to an equal number of ordinary shares, at a combined purchase price of $1.315 per ordinary share (or $1.314 per pre-funded warrant) and accompanying ordinary warrant, representing a premium of 10.5% to the Nasdaq official closing price of the ordinary shares on November 13, 2026 (the “Registered Offering”). The ordinary warrants will have an exercise price of $1.578 per share, will be exercisable immediately upon issuance, and will expire three years from the initial closing date. The pre-funded warrants will have an exercise price of $0.001 per share, will be exercisable immediately upon issuance, and will not expire until exercised in full.
Get started
Create a free account to read the full story.
